Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
56.16
+3.60 (6.85%)
At close: Feb 18, 2026, 4:00 PM EST
56.96
+0.80 (1.42%)
After-hours: Feb 18, 2026, 7:59 PM EST
Tempus AI Revenue
Tempus AI had revenue of $334.21M in the quarter ending September 30, 2025, with 84.72% growth. This brings the company's revenue in the last twelve months to $1.11B, up 72.58% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$1.11B
Revenue Growth
+72.58%
P/S Ratio
9.04
Revenue / Employee
$460,524
Employees
2,400
Market Cap
9.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | 62.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 13.30B |
| Veeva Systems | 3.08B |
| Privia Health Group | 2.04B |
| HealthEquity | 1.29B |
| Omnicell | 1.18B |
| Waystar Holding | 1.10B |
| 10x Genomics | 642.82M |
| Doximity | 637.78M |
TEM News
- 14 hours ago - Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm - Business Wire
- 6 days ago - Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform - Business Wire
- 6 days ago - Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States - Business Wire
- 8 days ago - Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24 - Business Wire
- 14 days ago - Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes - Business Wire
- 16 days ago - Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield - Business Wire
- 22 days ago - Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers - Business Wire
- 23 days ago - Tempus Logix Launches AI-Powered Calculator to End Hidden Fees and Price Fluctuation in Auto Transport - Newsfile Corp